



## Time is Vision – Emergent Evaluation & Management of CRAO

#### Tatiana Bakaeva, MD, PhD

Assistant Professor of Surgery
Assistant Professor of Neurology
The Warren Alpert Medical School at Brown University
Service Chief, Neuro-Ophthalmology
Brown University Health Ophthalmology
Providence, RI



## Financial Relationship Disclosure(s)

#### Tatiana Bakaeva, MD, PhD

Nothing to disclose



#### **Learning Objectives**

 Recognize the clinical presentation, underlying pathophysiology, and types of ocular stroke



#### **Learning Objectives**


- Recognize the clinical presentation, underlying pathophysiology, and types of ocular stroke
- Evaluate current and emerging strategies for the emergent management of CRAO, including modifications to existing stroke protocols ("Code Stroke Vision") and the role of thrombolytic therapy.



#### **Learning Objectives**

- Recognize the clinical presentation, underlying pathophysiology, and types of ocular stroke
- Evaluate current and emerging strategies for the emergent management of CRAO, including modifications to existing stroke protocols ("Code Stroke Vision") and the role of thrombolytic therapy.
- Assess the evidence supporting intravenous and intra-arterial thrombolysis in CRAO, understand limitations of traditional therapies, and review ongoing clinical trials shaping future management






#### Stroke

Volume 52, Issue 6, June 2021; Pages e282-e294 https://doi.org/10.1161/STR.00000000000000366



AHA SCIENTIFIC STATEMENT

- Acute CRAO is a form of ischemic stroke
- ~2 per 100,000 person per year; 10 per 100,000 for >80 years of age
- Nonarteritic (95%) ipsilateral ICA disease (~40-60%), cardiac emboli
- Arteritic (5%, usually GCA)









AHA SCIENTIFIC STATEMENT

- Acute CRAO is a form of ischemic stroke
- ~2 per 100,000 person per year; 10 per 100,000 for >80 years of age
- Nonarteritic (95%) ipsilateral ICA disease (~40-60%), cardiac emboli
- Arteritic (5%, usually GCA)











AHA SCIENTIFIC STATEMENT

- Acute CRAO is a form of ischemic stroke
- ~2 per 100,000 person per year; 10 per 100,000 for >80 years of age
- Nonarteritic (95%) ipsilateral ICA disease (~40-60%), cardiac emboli
- Arteritic (5%, usually GCA)









Sudden monocular painless vision loss













Sudden monocular painless vision loss
















- Sudden monocular painless vision loss
- ~30% patients have cilioretinal artery sparing of central vision
- Can affect branch of the retinal artery (BRAO) partial vision loss










- Sudden monocular painless vision loss
- ~30% patients have cilioretinal artery sparing of central vision
- Can affect branch of the retinal artery (BRAO) partial vision loss







- Sudden monocular painless vision loss
- ~30% patients have cilioretinal artery sparing of central vision
- Can affect branch of the retinal artery (BRAO) partial vision loss
- Poor spontaneous recovery ~18% regain functional visual acuity





IV thrombolysis, IA thrombolysis

• ~40-50% rate of clinical recovery when treated within 4.5 hours (IV) or 6

hours (IA) of onset

#### **Stroke**

Volume 51, Issue 7, July 2020; Pages 2018-2025 https://doi.org/10.1161/STROKEAHA.119.028743



#### CLINICAL AND POPULATION SCIENCES

#### Intravenous Fibrinolysis for Central Retinal Artery Occlusion

A Cohort Study and Updated Patient-Level Meta-Analysis

Brian Mac Grory, MB BCh BAO, MRCP, Alex Nackenoff, PhD, Sven Poli, MD, Martin S. Spitzer, MD, Max Nedelmann, MD, Benoit Guillon, MD, Cécile Preterre, MD, Celia S. Chen, MBBS, PhD, Andrew W. Lee, MBBS, MPH, Shadi Yaghi, MD, Christoph Stretz, MD, Idrees Azher, MD, John Paddock, MD, Tatiana Bakaeva. MD PhD. David M. Greer. MD. MA. Julie G.

Shulman, MD, Robert G. Kowalski, MBE International Journal of Stroke Volume 12, Issue 7, October 20 (Stroke Volume 12, Issue 7, October 20 (Stroke Organiza https://doi-org.revproxy.brown.and Matthew Schrag, MD, PhD

International Journal of Stroke
Volume 12, Issue 7, October 2017, Pages 720-723
© 2017 World Stroke Organization, Article Reuse Guidelines
https://doi-org.revproxy.brown.edu/10.1177/1747493016687578

#### Research

Management of acute central retinal artery occlusion: Intravenous thrombolysis is feasible and safe

Cécile Préterre<sup>1</sup>, Gaelle Godeneche<sup>2</sup>, Xavier Vandamme<sup>2</sup>, Thomas Ronzière<sup>3</sup>, Matthias Lamy<sup>4</sup>, Christophe Breuilly<sup>5</sup>, Cédric Urbanczyk<sup>6</sup>, Valérie Wolff<sup>7</sup>, Pierre Lebranchu<sup>8</sup>, Mathieu Sevin-Allouet<sup>1</sup>, and Benoit Guillon<sup>1</sup>

# Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion A Patient-Level Meta-analysis

Matthew Schrag, MD<sup>1</sup>; Teddy Youn, MD<sup>1</sup>; Joseph Schindler, MD<sup>1</sup>; Howard Kirshner, MD<sup>2</sup>; David Greer, MD<sup>1</sup>

JAMA Neurol. 2015;72(10):1148-1154. doi:10.1001/jamaneurol.2015.1578

#### RESEARCH ARTICLE

**\$**SAGE

iournals

Intravenous thrombolysis in acute central retinal artery occlusion – A prospective interventional case series


Maximilian Schultheiss<sup>1,2</sup>, Florian Härtig<sup>3</sup>, Martin S. Spitzer<sup>1,2</sup>, Nicolas Feltgen<sup>4</sup>, Bernhard Spitzer<sup>5</sup>, Johannes Hüsing<sup>6</sup>, André Rupp<sup>7</sup>, Ulf Ziemann<sup>3</sup>, Karl U. Bartz-Schmidt<sup>2</sup>, Sven Poli<sup>3</sup>\*



IV thrombolysis, IA thrombolysis

~40-50% rate of clinical recovery when treated within 4.5 hours (IV) or 6

hours (IA) of onset



Stroke • New online • https://doi.org/10.1161/STROKEAHA.124.049955

Early Thrombolysis and Outcomes in Central Retinal Artery Occlusion: An

Individual Participant Data Meta-Analysis

Jim S. Xie, MD <sup>10</sup>, Kirill Zaslavsky, MD, PhD <sup>10</sup>, Yuri Chaban, MD, MSc <sup>10</sup>, Adrien Lusterio, HBSc <sup>10</sup>, Hargun Kaur, MD, Yasmin Motekalem, MD, Dena Zeraatkar, PhD, ... <u>SHOW ALL</u> ... for the Assessment Group for Interventional Lysis in Eye (AGILE) | <u>AUTHOR INFO & AFFILIATIONS</u>

Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion

A Patient-Level Meta-analysis

Matthew Schrag, MD<sup>1</sup>; Teddy Youn, MD<sup>1</sup>; Joseph Schindler, MD<sup>1</sup>; Howard Kirshner, MD<sup>2</sup>; David Greer, MD<sup>1</sup>

≫ Author Affiliations | Article Information

RESEARCH ARTICLE

JAMA Neurol. 2015;72(10):1148-1154. doi:10.1001/jamaneurol.2015.1578

travenous thrombolysis in acute central etinal artery occlusion – A prospective terventional case series

ximilian Schultheiss<sup>1,2</sup>, Florian Härtig<sup>3</sup>, Martin S. Spitzer<sup>1,2</sup>, Nicolas Feltgen<sup>4</sup>, rnhard Spitzer<sup>5</sup>, Johannes Hüsing<sup>6</sup>, André Rupp<sup>7</sup>, Ulf Ziemann<sup>3</sup>, Karl U. Bartz-Schmidt<sup>2</sup>, en Poli<sup>3</sup>\*



Azher, MD, John Pa

Shulman, MD, Robe

Mistry, MBBS, Kierst

and Matthew Schrad

IV thrombolysis, IA thrombolysis

~40-50% rate of clinical recovery when treated within 4.5 hours (IV) or 6 hours (IA) of onset

Intravenous Fibringlytic Therapy in



#### Prospective randomized controlled studies

- THEIA (France) ID NCT03197194
  - IV Alteplase within 4.5 hours vs ASA 300 mg
  - N=70
  - Data collection completed, results not published yet



#### Prospective randomized controlled studies

- THEIA (France) ID NCT03197194
  - IV Alteplase within 4.5 hours vs ASA 300 mg
  - N=70
  - Data collection completed, results not published yet
- TenCRAOS (Norway) ID NCT04526951
  - IV Tenecteplase within 4.5 hours vs ASA 300 mg
  - N=78
  - Data collection completed, results not published yet



#### Prospective randomized controlled studies

- THEIA (France) ID NCT03197194
  - IV Alteplase within 4.5 hours vs ASA 300 mg
  - N=70
  - Data collection completed, results not published yet
- TenCRAOS (Norway) ID NCT04526951
  - IV Tenecteplase within 4.5 hours vs ASA 300 mg
  - N=78
  - Data collection completed, results not published yet
- REVISION (Germany) ID NCT04965038
  - IV Alteplase within 4.5 hours vs Placebo
  - N=422
  - Currently recruiting



Stroke • New online • https://doi.org/10.1161/STROKEAHA.124.049955

#### Prospective ra

- THEIA (France
  - IV Alteplase
  - N=70
  - Data collection

Early Thrombolysis and Outcomes in Central Retinal Artery Occlusion: An Individual Participant Data Meta-Analysis

Jim S. Xie, MD , Kirill Zaslavsky, MD, PhD , Yuri Chaban, MD, MSc , Adrien Lusterio, HBSc , Hargun Kaur, MD, Yasmin Motekalem, MD, Dena Zeraatkar, PhD, ... SHOW ALL ... for the Assessment Group for Interventional Lysis in Eye (AGILE) AUTHOR INFO & AFFILIATIONS

• TenCRAOS (N

- "A randomized controlled trial would require 95 participants per group to achieve 80% power to detect an odds ratio of 3.0 for recovery from severe vision loss".
- REVISION (Germany) ID NCT04965038
  - IV Alteplase within 4.5 hours vs Placebo
  - N=422
  - Currently recruiting



#### Central Retinal Artery Occlusion (CRAO) - Conservative Treatments

- anterior chamber paracentesis
- topical intraocular pressure-lowering agents
- systemic β-blockade
- sublingual isosorbide dinitrate
- carbogen therapy
- breathing into a paper bag
- ocular massage



#### Central Retinal Artery Occlusion (CRAO) - Conservative Treatments

- anterior chamber paracentesis
- topical intraocular pressure-lowering agents
- systemic β-blockade
- sublingual isosorbide dinitrate
- carbogen therapy
- breathing into a paper bag
- ocular massage

## No better than placebo





#### Central Retinal Artery Occlusion (CRAO) – Hyperbaric Oxygenation

- Under normal conditions: ~60% of retinal oxygen comes from the choroidal circulation
- Hyperbaric oxygen: choroidal diffusion can supply the entire retina
- Retrospective case series: early HBOT may improve visual outcomes in CRAO
- Higher risk of retinal neovascularization

## AMERICAN JOURNAL OF OPHTHALMOLOGY®


Outcomes of Hyperbaric Oxygen Treatment for Central Retinal Artery Occlusion: A Single Center Experience

BOYOUNG M. KIM", KENNY Y. WANG", TIMOTHY T. XU, SARA J. HOOSHMAND, GARY N. TOUPS, MARTHA P. MILLMAN, LAWRENCE W. STEINKRAUS, ANDREA A. TOOLEY, ANDREW J. BARKMEIER<sup>\$</sup>, AND JOHN J. CHEN<sup>\$</sup>



































GCA ROS: headaches, amaurosis, jaw claudication, scalp tenderness, fever / chills / night sweats, unexplained weight loss, malaise, myalgia or polyarthralgia.



#### Central Retinal Artery Occlusion (CRAO) - Barriers to Care

- Lack of public awareness about the urgency of acute vision loss
- ~30% of patients present to outpatient ophthalmology or optometry clinics
- ~25% arrive at the ED within 4.5-hour window from last known well




#### Central Retinal Artery Occlusion (CRAO) - Barriers to Care

- La
- ~3 clir
- ~2

WHEN IT COMES TO STROKE,

BEFAST CALL 911

Any one of these sudden SIGNS could mean a STROKE



urgency of acute vision loss ent ophthalmology or optometry

bur window from last known well





#### Central Retinal Artery Occlusion (CRAO) - Barriers to Care

La

~3

clir

~2

WHEN IT COMES TO STROKE,

BE FAST CALL 911

Any one of these sudden SIGNS could mean a STROKE

urgency of acute vision loss ent ophthalmology or optometry



